TrialBreast cancer (Tokyo, Japan)2023

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).

Kenji Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.